Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03969992 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
A Phase 2 study, sponsored by Aerogen Pharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
NCT03969992: Completed Phase 2 study, sponsored by Aerogen Pharma Limited.
NCT03969992 is a Phase 2 study that has completed, run by Aerogen Pharma Limited. The registered enrollment target is 261 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03969992, a Phase 2 study, has completed, sponsored by Aerogen Pharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
Study Summary
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
Primary Outcome
Number of patients who require intubation/cannulation with bolus surfactant instillation
Interventions
- DRUG AeroFact
- OTHER nCPAP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2024-08-05 |
| Phase | Phase 2 |
What the finished NCT03969992 record still lists
NCT03969992 is an interventional study that assigns participants to a tested intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% higher).
The record links to 0 conditions, and to 2 interventions - of which AeroFact is the first listed.
NCT03969992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03969992 about?
NCT03969992 is a clinical study titled "A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact". The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
What is the current status of trial NCT03969992?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2020-03-04. Estimated completion is 2024-08-05.
What interventions are being tested in trial NCT03969992?
The interventions under investigation include: AeroFact (DRUG), nCPAP (OTHER).
Who is sponsoring clinical trial NCT03969992?
This trial is sponsored by Aerogen Pharma Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03969992's enrollment target sits among peer trials
261 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124912 · 261 participants · NA
REMASTer: REcurrent Brain Metastases After SRS Trial
- NCT06559891 · 261 participants · NA
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI